11/18/2024
5:16 AM | Pontifax Management III G.P. Ltd. (0001726335) (Filed by)
UroGen Pharma (Subject)
| Form SC 13D/A | |
11/14/2024
6:46 PM | Point72 Asset Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
4:46 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
11:04 AM | MENORA MIVTACHIM HOLDINGS LTD. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
7:37 AM | COWEN AND COMPANY, LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
5:44 AM | RTW INVESTMENTS, LP (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/12/2024
8:30 AM | Adage Capital Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
|
11/08/2024
1:17 PM | BlackRock, Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024
12:50 PM | MORGAN STANLEY (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:04 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
10/09/2024
3:21 PM | Degnan Chris (Reporting)
UroGen Pharma (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/09/2024
3:22 PM | Degnan Chris (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
7:18 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/24/2024
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/12/2024
12:51 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
12:54 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
12:50 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
6:16 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
7:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/08/2024
3:30 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
8:06 AM | BUTITTA CYNTHIA M (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:07 AM | UroGen Pharma (Issuer)
WEN LEANA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:08 AM | Robinson James A. Jr. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:09 AM | Holden Stuart (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:10 AM | UroGen Pharma (Issuer)
Wildman Daniel George (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Cohen Fred E (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Belldegrun Arie (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/09/2024
4:30 PM | UroGen Pharma (Filer)
| Form ARS | |
06/24/2024
4:25 PM | COWEN AND COMPANY, LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/24/2024
3:51 PM | Point72 Asset Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/18/2024
4:07 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/13/2024
9:51 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/11/2024
12:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
5:16 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
1:22 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad) The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget!
We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] |
04/29/2024
7:18 AM | UroGen Pharma (Filer)
| Form 10-K/A | |
03/20/2024
3:38 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
12:48 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024
7:16 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:17 AM | UroGen Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/04/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/01/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/22/2024
8:23 AM | Arkin Moshe (Filed by)
UroGen Pharma (Subject)
| Form SC 13D/A | |
02/14/2024
6:07 AM | RTW INVESTMENTS, LP (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/12/2024
4:47 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/12/2024
4:43 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/07/2024
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/05/2024
8:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/05/2024
8:16 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/02/2024
6:04 PM | Barrett Elizabeth A. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:05 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:07 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:12 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
1:18 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/01/2024
9:13 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/01/2024
8:53 AM | Smith Jason Drew (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024
3:16 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2024
7:04 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/29/2023
3:30 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
